stoxline Quote Chart Rank Option Currency Glossary
iCAD, Inc. (ICAD)
1.66  0.02 (1.22%)    12-08 16:00
Open: 1.64
High: 1.685
Volume: 149,461
Pre. Close: 1.64
Low: 1.57
Market Cap: 44(M)
Technical analysis
2023-12-08 4:43:57 PM
Short term     
Mid term     
Targets 6-month :  2.06 1-year :  2.41
Resists First :  1.76 Second :  2.06
Pivot price 1.51
Supports First :  1.45 Second :  1.25
MAs MA(5) :  1.66 MA(20) :  1.47
MA(100) :  1.99 MA(250) :  1.85
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  78.6 D(3) :  80
RSI RSI(14): 57.4
52-week High :  3.97 Low :  1.04
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ICAD ] has closed below upper band by 28.8%. Bollinger Bands are 15.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.69 - 1.69 1.69 - 1.7
Low: 1.55 - 1.56 1.56 - 1.57
Close: 1.65 - 1.66 1.66 - 1.67
Company Description

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

Headline News

Wed, 29 Nov 2023
RSNA23: iCAD, GE HealthCare Integrate to Advance Breast Cancer Detection with AI - HIT Consultant

Tue, 28 Nov 2023
iCAD's AI-powered solutions to Help Accelerate Breast - GlobeNewswire

Tue, 28 Nov 2023
iCAD and CancerIQ Announce Partnership to Integrate AI-Enabled Technology With Best-in-Class Risk Assessment ... - Imaging Technology News

Mon, 27 Nov 2023
iCad AI tech accurately predicts breast cancer risk, provides heart disease insights - Mass Device

Mon, 27 Nov 2023
iCAD's ProFound AI Can Predict 1-2 Year Risk for Breast - GlobeNewswire

Thu, 16 Nov 2023
This iCAD Insider Increased Their Holding In The Last Year - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Medical Devices
Shares Out 26 (M)
Shares Float 25 (M)
Held by Insiders 6 (%)
Held by Institutions 36.8 (%)
Shares Short 597 (K)
Shares Short P.Month 591 (K)
Stock Financials
EPS -0.5
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.17
Profit Margin -39.5 %
Operating Margin -30 %
Return on Assets (ttm) -16.4 %
Return on Equity (ttm) -36.6 %
Qtrly Rev. Growth -6.6 %
Gross Profit (p.s.) 0.76
Sales Per Share 0.96
EBITDA (p.s.) -0.49
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -3.39
PEG Ratio -0.4
Price to Book value 1.4
Price to Sales 1.72
Price to Cash Flow -6.59
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android